An interventional study to assess patient-reported outcome measures in bradalumab treated patients with moderate to severe plaque psoriasis in Japan
Phase of Trial: Phase II
Latest Information Update: 08 Jul 2019
Price : $35 *
At a glance
- Drugs Brodalumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Kyowa Hakko Kirin
- 05 Jul 2019 Status changed from active, no longer recruiting to discontinued.
- 21 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 25 Apr 2018 Status changed from not yet recruiting to recruiting.